Moreover, this approach is considered as a promising tool to manipulate (downregulate) CR protein levels in vivo at early stages of MM development, thus allowing to monitoring cancer progression within the tumor microenvironment. This evidence concerns the gene CALB2 and Miyoshi myopathy.